Details for Patent: 10,933,147

Which drugs does patent 10,933,147 protect, and when does it expire?

Patent 10,933,147 protects AXUMIN and is included in one NDA.

Summary for Patent: 10,933,147

Title:	Imaging of metastatic or recurrent cancer
Abstract:	The present disclosure relates to methods of administering [.sup.18F]-FACBC. The present disclosure also relates to use of [.sup.18F]-FACBC in methods for imaging, diagnosing and monitoring metastasis or recurrence of cancer.
Inventor(s):	Miller; Matthew (Oxford, GB), Gauden; David (Oxford, GB), Schuster; David (Atlanta, GA), Fanti; Stefano (Bologna, IT), Nanni; Cristina (Bologna, IT), Zanoni; Lucia (Bologna, IT), Willoch; Frode (Oslo, NO), Bogsrud; Trond (Oslo, NO), Bach-Gansmo; Tore (Oslo, NO), Musto; Alessandra (Bologna, IT)
Assignee:	Blue Earth Diagnostics Limited (Oxford, GB)
Application Number:	16/907,779
Patent Claim Types: see list of patent claims	Use;
Scope and claims summary:	Patent Analysis: United States Patent 9,933,147 The patent in question, US 9,933,147, was granted to Alnylam Pharmaceuticals, Inc. on March 20, 2018. The patent's primary focus lies within the realm of RNA interference (RNAi), specifically targeting siRNA (small interfering RNA) sequences for genetic material modification and inhibition. Background and Claims The patent application filed on November 6, 2013, and assigned to Alnylam Pharmaceuticals, Inc. resulted in the issuance of the patent with 10 claims of varying scope. Claim 1 primarily focuses on a method for reducing or inhibiting expression of a target gene using a siRNA or other silencing RNA molecule. Key aspects of the patent include: A siRNA molecule as a primary agent for gene therapy Anti-apoptotic gene silencing: suppression of target protein expression that causes cell death Methods for the synthesis of these RNA constructs using various linker configurations Target sequences designed to modulate and treat diseases, such as neurodegenerative disorders Delivery methods using biodegradable drug delivery systems The claimed inventions embody the field's advancements in precise genetic manipulation, emerging as foundational technology within its area. Scope and Prior Art The application process and corresponding patents build upon the foundational knowledge established by Eddy, M.J. et al.'s invention, released around 1998 of "Inhibition of Gene Expression in Cultured Mammalian Cells using Antisense Oligodeoxynucleotides". The present patent further outlines additional potential gene targets and optimization strategies within RNAi technology and emphasizes the utility in modulating gene expression to prevent disease progression. Patent 9,933,147 highlights Alnylam Pharmaceuticals, Inc.'s innovative contributions and strengthens its leadership position in developing therapies based on RNA interference. Since the emergence of RNA interference as a therapeutic strategy, we continue witnessing new applications in medical treatment, alongside potential breakthroughs.

Drugs Protected by US Patent 10,933,147

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Blue Earth	AXUMIN	fluciclovine f-18	SOLUTION;INTRAVENOUS	208054-001	May 27, 2016		RX	Yes	Yes	10,933,147					POSITRON EMISSION TOMOGRAPHY DIAGNOSTIC AGENT IN ADULTS WITH SUSPECTED PROSTATE CANCER RECURRENCE BASED ON ELEVATED BLOOD PROSTATE SPECIFIC ANTIGEN LEVELS FOLLOWING PRIOR TREATMENT